Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica
Published in: Acta Neuropathologica 3/2012

01-09-2012 | Review

The genetics and neuropathology of Parkinson’s disease

Published in: Acta Neuropathologica | Issue 3/2012

Login to get access

Abstract

There has been tremendous progress toward understanding the genetic basis of Parkinson’s disease and related movement disorders. We summarize the genetic, clinical and pathological findings of autosomal dominant disease linked to mutations in SNCA, LRRK2, ATXN2, ATXN3, MAPT, GCH1, DCTN1 and VPS35. We then discuss the identification of mutations in PARK2, PARK7, PINK1, ATP13A2, FBXO7, PANK2 and PLA2G6 genes. In particular we discuss the clinical and pathological characterization of these forms of disease, where neuropathology has been important in the likely coalescence of pathways highly relevant to typical PD. In addition to the identification of the causes of monogenic forms of PD, significant progress has been made in defining genetic risk loci for PD; we discuss these here, including both risk variants at LRRK2 and GBA, in addition to discussing the results of recent genome-wide association studies and their implications for PD. Finally, we discuss the likely path of genetic discovery in PD over the coming period and the implications of these findings from a clinical and etiological perspective.
Literature
1.
2.
Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351:1972–1977PubMedCrossRef
3.
4.
Ballana E, Govea N, de Cid R et al (2008) Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations. Hum Mutat 29:248–257. doi:10.​1002/​humu.​20639 PubMedCrossRef
5.
Bardien S, Lesage S, Brice A, Carr J (2011) Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson’s disease. Parkinsonism Relat Disord 17:501–508. pii: S1353-8020(10)00287-7PubMedCrossRef
6.
7.
Bonifati V, Rohe CF, Breedveld GJ et al (2005) Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65:87–95PubMedCrossRef
8.
Bras JM, Guerreiro RJ, Ribeiro MH et al (2005) G2019S dardarin substitution is a common cause of Parkinson’s disease in a Portuguese cohort. Mov Disord : Official J Mov Disord Soc 20:1653–1655. doi:10.​1002/​mds.​20682 CrossRef
9.
10.
11.
12.
Clark IE, Dodson MW, Jiang C et al. (2006) Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441: 1162–1166
13.
Consortium UKPsD, Wellcome Trust Case Control Consortium, Spencer CC et al (2011) Dissection of the genetics of Parkinson’s disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 20:345–353. pii: ddq469PubMedCrossRef
14.
Criscuolo C, Volpe G, De Rosa A et al (2006) PINK1 homozygous W437X mutation in a patient with apparent dominant transmission of parkinsonism. Mov Disord: Off J Mov Disord Soc 21:1265–1267. doi:10.​1002/​mds.​20933 CrossRef
15.
16.
Di Fonzo A, Chien HF, Socal M et al (2007) ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68:1557–1562. pii: 68/19/1557PubMedCrossRef
17.
18.
19.
20.
Djarmati A, Hagenah J, Reetz K et al (2009) ATP13A2 variants in early-onset Parkinson’s disease patients and controls. Mov Disord: Off J Mov Disord Soc 24:2104–2111. doi:10.​1002/​mds.​22728 CrossRef
21.
22.
23.
Edwards TL, Scott WK, Almonte C et al (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74:97–109PubMedCrossRef
24.
Farrer M, Chan P, Chen R et al (2001) Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 50:293–300PubMedCrossRef
25.
26.
27.
28.
Fung HC, Scholz S, Matarin M et al (2006) Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 5:911–916. pii: S1474-4422(06)70578-6PubMedCrossRef
29.
Furtado S, Payami H, Lockhart PJ et al (2004) Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord : Off J Mov Disord Soc 19:622–629. doi:10.​1002/​mds.​20074 CrossRef
30.
Gaig C, Marti MJ, Ezquerra M, Rey MJ, Cardozo A, Tolosa E (2007) G2019S LRRK2 mutation causing Parkinson’s disease without Lewy bodies. J Neurol Neurosurg Psychiatry 78:626–628. doi:jnnp.​2006.​107904 PubMedCrossRef
31.
32.
33.
34.
Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65:1353–1357PubMedCrossRef
35.
36.
Goldwurm S, Tunesi S, Tesei S et al (2011) Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson’s disease. Mov Disord: Off J Mov Disord Soc. doi:10.​1002/​mds.​23807
37.
Gouider-Khouja N, Larnaout A, Amouri R et al (2003) Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism Relat Disord 9:247–251 pii: S1353802003000166PubMedCrossRef
38.
Gwinn-Hardy K, Chen JY, Liu HC et al (2000) Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 55:800–805PubMedCrossRef
39.
Gwinn-Hardy K, Singleton A, O’Suilleabhain P et al (2001) Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. Arch Neurol 58:296–299PubMedCrossRef
40.
Gwinn K, Devine MJ, Jin LW et al (2011) Clinical features, with video documentation, of the original familial Lewy body parkinsonism caused by alpha-synuclein triplication (Iowa kindred). Mov Disord : Off J Mov Disord Soc 26:2134–2136CrossRef
41.
42.
Hasegawa K, Stoessl AJ, Yokoyama T, Kowa H, Wszolek ZK, Yagishita S (2009) Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism Relat Disord 15:300–306 pii: S1353-8020(08)00233-2PubMedCrossRef
43.
Hayashi S, Wakabayashi K, Ishikawa A et al (2000) An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord: Off J Mov Disord Soc 15:884–888CrossRef
44.
45.
46.
Hernandez D, Paisan Ruiz C, Crawley A et al (2005) The dardarin G 2019 S mutation is a common cause of Parkinson’s disease but not other neurodegenerative diseases. Neurosci Lett 389:137–139. pii:S0304-3940(05)00861-XPubMedCrossRef
47.
48.
Hjermind LE, Johannsen LG, Blau N et al (2006) Dopa-responsive dystonia and early-onset Parkinson’s disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord : Off J Mov Disord Soc 21:679–682. doi:10.​1002/​mds.​20773 CrossRef
49.
Hutton M, Lendon CL, Rizzu P et al (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702–705. doi:10.​1038/​31508 PubMedCrossRef
50.
51.
International Parkinson’s Disease Genomics Consortium, Wellcome Trust Case Control Consortium (2011) A two-stage meta-analysis identifies several new loci for Parkinson’s disease. PLoS Genet 7: e1002142. doi:10.​1371/​journal.​pgen.​1002142
52.
International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649. [pii:S0140-6736(10)62345-8]PubMedCrossRef
53.
Kachergus J, Mata IF, Hulihan M et al (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672–680. pii:S0002-9297(07)62878-XPubMedCrossRef
54.
55.
56.
57.
Khan NL, Brooks DJ, Pavese N et al (2002) Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125:2248–2256PubMedCrossRef
58.
Khan NL, Jain S, Lynch JM et al (2005) Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson’s disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786–2796. doi:awh667 PubMedCrossRef
59.
60.
Kruer MC, Hiken M, Gregory A et al (2011) Novel histopathologic findings in molecularly-confirmed pantothenate kinase-associated neurodegeneration. Brain 134:947–958PubMedCrossRef
61.
62.
63.
Kruger R, Vieira-Saecker AM, Kuhn W et al (1999) Increased susceptibility to sporadic Parkinson’s disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Neurol 45:611–617PubMedCrossRef
64.
Kurian MA, Morgan NV, MacPherson L et al (2008) Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 70:1623–1629PubMedCrossRef
65.
66.
Lesage S, Durr A, Tazir M et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 354:422–423PubMedCrossRef
67.
Lesage S, Leutenegger AL, Ibanez P et al (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330–332 pii: S0002-9297(07)62924-3PubMedCrossRef
68.
69.
Lincoln SJ, Maraganore DM, Lesnick TG et al (2003) Parkin variants in North American Parkinson’s disease: cases and controls. Mov Disord : Off J Mov Disord Soc 18:1306–1311. doi:10.​1002/​mds.​10601 CrossRef
70.
71.
72.
Lynch T, Sano M, Marder KS et al (1994) Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 44:1878–1884PubMedCrossRef
73.
74.
Maraganore DM, de Andrade M, Elbaz A et al (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296:661–670 pii: 296/6/661PubMedCrossRef
75.
Maraganore DM, de Andrade M, Lesnick TG et al (2005) High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77:685–693 pii: S0002-9297(07)63354-0PubMedCrossRef
76.
77.
Marti-Masso JF, Ruiz-Martinez J, Bolano MJ et al (2009) Neuropathology of Parkinson’s disease with the R1441G mutation in LRRK2. Mov Disord: Off J Mov Disord Soc 24:1998–2001. doi:10.​1002/​mds.​22677 CrossRef
78.
79.
Matsuda N, Sato S, Shiba K et al (2010) PINK1 stabilized by mitochondrial depolarization recruits parkin to damaged mitochondria and activates latent parkin for mitophagy. J Cell Biol 189:211–221. doi:10.​1083/​jcb.​200910140 PubMedCrossRef
80.
Mellick GD, Siebert GA, Funayama M et al (2009) Screening PARK genes for mutations in early-onset Parkinson’s disease patients from Queensland, Australia. Parkinsonism Relat Disord 15:105–109. [pii:S1353-8020(08)00108-9]PubMedCrossRef
81.
Miller DW, Hague SM, Clarimon J et al (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62:1835–1838PubMedCrossRef
82.
Morgan NV, Westaway SK, Morton JE et al (2006) PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet 38:752–754PubMedCrossRef
83.
Mori H, Kondo T, Yokochi M et al (1998) Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 51:890–892PubMedCrossRef
84.
85.
Neudorfer O, Giladi N, Elstein D et al (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89:691–694PubMedCrossRef
86.
87.
Ning YP, Kanai K, Tomiyama H et al (2008) PARK9-linked parkinsonism in eastern Asia: mutation detection in ATP13A2 and clinical phenotype. Neurology 70:1491–1493PubMedCrossRef
88.
89.
Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31:763–780. doi:10.​1002/​humu.​21277 PubMedCrossRef
90.
Obi T, Nishioka K, Ross OA et al (2008) Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70:238–241PubMedCrossRef
91.
Ozelius LJ, Senthil G, Saunders-Pullman R et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in Ashkenazi Jews. N Engl J Med 354:424–425PubMedCrossRef
92.
93.
94.
Paisan-Ruiz C, Guevara R, Federoff M et al (2010) Early-onset l-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord: Off J Mov Disord Soc 25:1791–1800. doi:10.​1002/​mds.​23221 CrossRef
95.
96.
Paisan-Ruiz C, Nath P, Wood NW, Singleton A, Houlden H (2008) Clinical heterogeneity and genotype-phenotype correlations in hereditary spastic paraplegia because of Spatacsin mutations (SPG11). Eur J Neurol: Off J Eur Fed Neurol Soc 15:1065–1070. doi:10.​1111/​j.​1468-1331.​2008.​02247.​x
97.
Paisan-Ruiz C, Scopes G, Lee P, Houlden H (2009) Homozygosity mapping through whole genome analysis identifies a COL18A1 mutation in an Indian family presenting with an autosomal recessive neurological disorder. Am J Med Genet Part B, Neuropsychiatric Genet: Off Publ Int Soc Psychiatric Genet 150B:993–997. doi:10.​1002/​ajmg.​b.​30929
98.
99.
Park J, Lee SB, Lee S et al (2006) Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441:1157–1161PubMedCrossRef
100.
Perry TL, Bratty PJ, Hansen S, Kennedy J, Urquhart N, Dolman CL (1975) Hereditary mental depression and Parkinsonism with taurine deficiency. Arch Neurol 32:108–113PubMedCrossRef
101.
Polymeropoulos MH, Higgins JJ, Golbe LI et al (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274:1197–1199PubMedCrossRef
102.
Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047PubMedCrossRef
103.
104.
Ramirez A, Heimbach A, Grundemann J et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184–1191PubMedCrossRef
105.
Rieley MB, Stevenson DA, Viskochil DH, Tinkle BT, Martin LJ, Schorry EK (2011) Variable expression of neurofibromatosis 1 in monozygotic twins. Am J Med Genet Part A 155A:478–485. doi:10.​1002/​ajmg.​a.​33851 PubMed
106.
107.
Samaranch L, Lorenzo-Betancor O, Arbelo JM et al (2010) PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 133:1128–1142PubMedCrossRef
108.
Sasaki S, Shirata A, Yamane K, Iwata M (2004) Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology 63:678–682PubMedCrossRef
109.
Satake W, Nakabayashi Y, Mizuta I et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet 41:1303–1307PubMedCrossRef
110.
Schneider SA, Paisan-Ruiz C, Quinn NP et al (2010) ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord : Off J Mov Disord Soc 25:979–984. doi:10.​1002/​mds.​22947 CrossRef
111.
112.
Shojaee S, Sina F, Banihosseini SS et al (2008) Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet 82:1375–1384. [pii:S0002-9297(08)00314-5]PubMedCrossRef
113.
Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661PubMedCrossRef
114.
Simon-Sanchez J, Schulte C, Bras JM et al (2009) Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet 41:1308–1312PubMedCrossRef
115.
Simon-Sanchez J, van Hilten JJ, van de Warrenburg B et al (2011) Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet 19:655–661PubMedCrossRef
116.
117.
118.
Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 251:205–208PubMedCrossRef
119.
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469–6473PubMedCrossRef
120.
121.
Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA (2001) Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 49:313–319PubMedCrossRef
122.
Subramony SH, Hernandez D, Adam A et al (2002) Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. Mov Disord: Off J Mov Disord Soc 17:1068–1071. doi:10.​1002/​mds.​10241 CrossRef
123.
Tanner CM, Ottman R, Goldman SM et al (1999) Parkinson disease in twins: an etiologic study. JAMA 281:341–346PubMedCrossRef
124.
125.
126.
Thomas M, Hayflick SJ, Jankovic J (2004) Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord: Off J Mov Disord Soc 19:36–42. doi:10.​1002/​mds.​10650 CrossRef
127.
128.
van de Warrenburg BP, Lammens M, Lucking CB et al (2001) Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56:555–557PubMedCrossRef
129.
Vilarino-Guell C, Wider C, Ross OA et al (2011) VPS35 mutations in Parkinson disease. Am J Hum Genet 89:162–167 pii:S0002-9297(11)00242-4PubMedCrossRef
130.
131.
Wider C, Dickson DW, Wszolek ZK (2010) Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neuro-degenerative diseases 7:175–179. doi:10.​1159/​000289232 PubMed
132.
Wiest V, Eisenbarth I, Schmegner C, Krone W, Assum G (2003) Somatic NF1 mutation spectra in a family with neurofibromatosis type 1: toward a theory of genetic modifiers. Hum Mutat 22:423–427. doi:10.​1002/​humu.​10272 PubMedCrossRef
133.
Wilhelmsen KC, Lynch T, Pavlou E, Higgins M, Nygaard TG (1994) Localization of disinhibition–dementia–parkinsonism–amyotrophy complex to 17q21-22. Am J Hum Genet 55:1159–1165PubMed
134.
135.
136.
137.
Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28:345–349. doi:10.​1038/​ng572 PubMedCrossRef
138.
Zimprich A, Benet-Pages A, Struhal W et al (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89:168–175. [pii:S0002-9297(11)00261-8]PubMedCrossRef
139.
Zimprich A, Biskup S, Leitner P et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607. [pii:S0896627304007202]PubMedCrossRef
140.
Zuk O, Hechter E, Sunyaev SR, Lander ES (2012) The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci USA. doi:10.​1073/​pnas.​1119675109
Metadata
Title
The genetics and neuropathology of Parkinson’s disease
Publication date
01-09-2012
Published in
Acta Neuropathologica / Issue 3/2012
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI
https://doi.org/10.1007/s00401-012-1013-5

Other articles of this Issue 3/2012

Acta Neuropathologica 3/2012 Go to the issue

Commentary

Targeting intracerebral inflammation in multiple sclerosis: is it feasible?

Original Paper

Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain

Original Paper

Fingolimod attenuates ceramide-induced blood–brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes

Review

The genetics and neuropathology of frontotemporal lobar degeneration

Correspondence

Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas

Original Paper

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas